Christian Lange

USPTO Granted Patents = 22 (Patent Applications = 9)

CIPO Patents = 1 (Patent Applications = 14)

EPO Patents = 11 (Patent Applications = 28)

Average Co-Inventor Count = 9.9

ph-index = 6

Forward Citations = 83(Granted Patents)

Location History:

Holler, DE (2015 - 2021)
Frankfurt-am-Main, DE (2014 - 2024)

Company Filing History:

Pieris Pharmaceuticals Gmbh

patents

4. 1 out of 5,303

Leland Stanford Junior University

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12054552 - Humanized anti-IL-1R3 antibody and methods of use (2024-08-06),

2. 12054551 - FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides (2024-08-06),

3. 11965030 - Multispecific binding proteins with mutant fab domains (2024-04-23),

4. 11932704 - Trispecific and/or trivalent binding proteins (2024-03-19),

5. 11820809 - Multispecific antibodies facilitating selective light chain pairing (2023-11-21),

6. 11779651 - Bivalent, bispecific binding proteins for prevention or treatment of HIV infection (2023-10-10),

7. 11739160 - PseudoFab-based multispecific binding proteins (2023-08-29),

8. 11254737 - Multispecific binding molecules having specificity to dystroglycan and laminin-2 (2022-02-22),

9. 11192960 - Trispecific and/or trivalent binding proteins (2021-12-07),

10. 11129905 - Bivalent, bispecific binding proteins for prevention or treatment of HIV infection (2021-09-28),

11. 10947284 - Fusion molecules (2021-03-16),

12. 10906978 - Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 (2021-02-02),

13. 10882922 - Trispecific and/or trivalent binding proteins (2021-01-05),

14. 10626169 - Multispecific binding molecules having specificity to dystroglycan and laminin-2 (2020-04-21),

15. 10316071 - Fusion molecules (2019-06-11),

Title: Christian Lange: Innovator in Antibody Therapeutics

Introduction

Christian Lange, based in Frankfurt am Main, Germany, is a notable inventor with a remarkable portfolio of 22 patents. His work primarily focuses on advancements in antibody therapeutics, contributing significantly to the field of immunology and medicine.

Latest Patents

Among his latest patents, one stands out: the humanized anti-IL-1R3 antibody, which specifically binds to IL-1R3. This invention details an antibody comprising a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. The patent also describes a pharmaceutical composition containing this antibody, intended to treat autoimmune and autoinflammatory diseases. Another pivotal patent involves FGFR1/KLB targeting agonistic antigen-binding proteins and their conjugates with GLP-1R agonistic peptides. This innovation includes proteins with enhanced physico-chemical properties and addresses their application in medical therapies through specialized pharmaceutical compositions.

Career Highlights

Christian has held influential positions at prominent companies such as Sanofi and Pieris Pharmaceuticals GmbH, where he contributed to the development of cutting-edge biomedical therapies. His expertise in the field has helped shape innovative solutions for complex medical challenges.

Collaborations

Throughout his career, Christian has collaborated with esteemed colleagues, including Ercole Rao and Christian Beil. Together, they have driven forward the research and development of novel therapeutic approaches in antibody technology.

Conclusion

Christian Lange exemplifies the spirit of innovation in the biotechnology sector. With a robust portfolio of patents and collaborations, he continues to make significant strides in the development of antibody-based therapies that hold promise for the treatment of various diseases. His contributions not only highlight his expertise but also represent a pivotal advancement in medical science.

This text is generated by artificial intelligence and may not be accurate.